Treatment of solid tumors with standard chemotherapy often leads only to partial response. Thus, tumor recurrence after chemotherapy driven by tumor-reinitiating cells (TRICs) is a central problem in cancer therapy. Despite its importance, the mechanisms accounting for variable therapy response and tumor re-initiation in vivo are poorly understood. A significant problem in understanding this phenomenon in humans is the inaccessibility of matched clinical samples before and after chemotherapy from the same patient. Mouse models of cancer that closely mimic the human disease are useful tools to study the process of tumor re- initiation after chemotherapy. However, few studies have systematically utilized these models to understand chemotherapy response. Using a mouse model of human lung cancer, we have identified a subset of tumor cells that can be isolated by their cell surface markers and have an increased intrinsic resistance to chemotherapy. We utilized a Kras-driven lung tumor model crossed to a conditional transgenic reporter (tdRFP) in order to facilitate isolation of tumor cells by FACs. Cisplatin treatment of these mice leads to a dramatic decrease in the number of CD44+;tdRFP+ cells, suggesting that CD44- cells are chemotherapy resistant. Using an antibody that detects cisplatin-DNA adducts, we find that CD44- and CD44+ tumor cells have distinct DNA repair capacities. Chemoresistance in this model is associated with a dramatic increase in sphere-forming ability in vitro. In vitro sphere-forming ability is further enriched in a CD44-/CD24+ subpopulation. Thus, we have uncovered a relationship between chemoresistance and characteristics associated with cancer stem cells (cell surface marker heterogeneity, sphere formation). In this proposal, we will utilize mouse genetics, functional genomics and primary human lung cancer samples to elucidate the mechanism of chemoresistance and its relationship to the cancer stem cell phenotype in non-small cell lung cancer.

Public Health Relevance

How tumors respond to chemotherapy and why they become resistant is not completely understood. We will use a mouse model of lung cancer and primary human cancer samples to study the mechanisms of chemotherapy resistance. We focus primarily on understanding how tumor cells repair injury causes by chemotherapy and how they are able to repair this injury and survive.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Schools of Medicine
United States
Zip Code
Sayles, Leanne C; Breese, Marcus R; Koehne, Amanda L et al. (2018) Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov :
Brady, Jennifer J; Chuang, Chen-Hua; Greenside, Peyton G et al. (2016) An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency. Cancer Cell 29:697-710
Zheng, Yanyan; de la Cruz, Cecile C; Sayles, Leanne C et al. (2013) A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 24:59-74
Zheng, Yanyan; Moore, Helen; Piryatinska, Alexandra et al. (2013) Mathematical modeling of tumor cell proliferation kinetics and label retention in a mouse model of lung cancer. Cancer Res 73:3525-33
Vicent, Silvestre; Sayles, Leanne C; Vaka, Dedeepya et al. (2012) Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res 72:5744-56